巴西专利BR112015011036B1 Heterocyclic Substituted 2-Amino-quinazoline Derivatives, Pharmaceutical Composition

专利PDF首页>>巴西专利

专利附录

专利说明

权利要求

类似技术

同族专利

引用文献

法律状态

优先权

专利摘要:
HETEROCYCLIC SUBSTITUTED 2-AMINO-QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS. This invention relates to heterocyclic substituted 2-amino-quinazoline derivatives, processes for their preparation, pharmaceutical compositions, and their use in the treatment of viral infections.
公开号:BR112015011036B1
申请号:R112015011036-3
申请日:2013-11-15
公开日:2022-02-01
发明作者:Pierre Jean-Marie Bernard Raboisson；Tim Hugo Maria Jonckers；Werner Embrechts；David Craig Mc Gowan；Serge Maria Aloysius Pieters；Stefaan Julien Last
申请人:Janssen Sciences Ireland Uc；
IPC主号:

专利说明:

[001] This invention relates to heterocyclic substituted 2-amino-quinazoline derivatives, processes for their preparation, pharmaceutical compositions, and their use in the treatment of viral infections.
[002] The present invention relates to the use of heterocyclic substituted 2-amino-quinazoline derivatives in the treatment of viral infections, immune or inflammatory disorders, where modulation, or agonism, of toll-like receptors (TLRs) is involved. Toll-Type Receptors are primary transmembrane proteins characterized by a leucine-rich extracellular domain and a cytoplasmic extension that contains a conserved region. The innate immune system is able to recognize molecular patterns associated with pathogens through these TLRs expressed on the cell surface of certain types of immune cells. Recognition of foreign pathogens activates cytokine production and an up-regulation of costimulatory molecules in phagocytes. This leads to modulation of the behavior of T lymphocytes.
[003] It has been estimated that most mammalian species have between ten and fifteen types of Toll-like receptors. Thirteen TLRs (termed TLR1 to TLR13) have been identified in humans and mice together, and equivalent forms of many of these have been found in other mammalian species. However, equivalents of certain TLRs found in humans are not present in all mammals. For example, a gene encoding a protein analogous to TLR10 in humans is present in mice, but appears to have been damaged at some point in the past by a retrovirus. On the other hand, mice express TLRs 11, 12 and 13, none of which are represented in humans. Other mammals can express TLRs that are not found in humans. Other non-mammalian species may have TLRs distinct from mammals, as demonstrated by TLR14, which is found in the Takifugu pufferfish. This can complicate the process of using experimental animals as models of human innate immunity.
[004] For reviews of TLRs see the following journal articles. Hoffmann, J.A., Nature, 426, pp. 33-38, 2003; Akira, S., Takeda, K., and Kaisho, T., Annual Rev. Immunology, 21, pp. 335-376, 2003; Ulevitch, R.J., Nature Reviews: Immunology, 4, pp. 512-520, 2004.
[005] Compounds indicating activity at Toll Type receptors such as purine derivatives in WO 2006/117670, adenine derivatives in WO 98/01448 and WO 99/28321, and pyrimidines in WO 2009/067081 have previously been described.
[006] However, there is a strong need for new Toll-Type receptor modulators having preferential selectivity, higher potency, higher metabolic stability, and an improved safety profile compared to prior art compounds.
[007] According to the present invention there is provided a compound of formula (I)
or a pharmaceutically acceptable salt, tautomer(s), stereoisomeric forms, solvate or polymorph thereof, wherein
[008] R1 is any of the following structures:

[009] R2 is hydrogen, -O-(C1-3)alkyl, halogen, (C1-3)alkyl, -O-(C1-3)alkyl-O-(C1-3)alkyl or CH2OH ;
[0010] R3 is hydrogen, -O-(C1-3)-alkyl, halogen, (C1-3)-alkyl, or -C(=O)-R7 where R7 is -O-(C1-3)-alkyl , NH2, NH(CH3), N(CH3)2, N(CH3)alkyl-(C1-3), N(alkyl-(C1-3))2 or pyrrolidine;
[0011] R4 is hydrogen or fluorine;
[0012] R5 is (C1-3)-alkyl, fluoro-C1-3-alkyl or CH2OH;
[0013] R6 is NH2, NH(CH3) or N(CH3)2, (hetero)-anilines optionally substituted by one or more R8, R9, Ri0, Rii or Ri2 or (hetero)-benzylamines optionally substituted by one or more R8 , R9, Ri0, Rii, or Ri2,
[0014] R8, R9, Ri0, Rii and Ri2, which are the same or different, are each independently selected from hydrogen, (C1-3)-alkyl, -O- (C1-3)-alkyl, or halogen
[0015] and
[0016] R13 is hydrogen, (C1-3)-alkyl or (C1-3)-fluoro-alkyl.
[0017] Preferred compounds according to the invention are compounds numbered 12 and 29 as illustrated in Table II.
[0018] The compounds of formula (I) and their pharmaceutically acceptable salts, tautomer(s), stereoisomeric forms, solvate or polymorph have activity as pharmaceuticals, in particular as modulators of Toll-Type Receptor activity (especially TLR7 activity and/or or TLR8).
[0019] In a further aspect, the present invention provides a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt, tautomer, stereoisomeric form, solvate or polymorph thereof together with one or more pharmaceutically acceptable excipients, diluents or carriers. .
[0020] Furthermore, a compound of formula (I) or a pharmaceutically acceptable salt, tautomer, stereoisomeric form, solvate or polymorph thereof according to the present invention, or a pharmaceutical composition comprising said compound of formula (I) ) or a pharmaceutically acceptable salt, tautomer, stereoisomeric form, solvate or polymorph thereof can be used as a medicine.
[0021] Another aspect of the invention is that a compound of formula (I) or a pharmaceutically acceptable salt, tautomer, stereoisomeric form, solvate or polymorph thereof, or said pharmaceutical composition comprising said compound of formula (I) or a salt thereof, pharmaceutically acceptable tautomer, stereoisomeric form, solvate or polymorph may be used accordingly in the treatment of a disorder in which modulation of TLR7 and/or TLR8 is involved.
[0022] The term "-(C1-3)alkyl" refers to a straight-chain, branched-chain or cyclic saturated aliphatic hydrocarbon containing the specified number of carbon atoms.
[0023] The term "fluoro-alkyl-(C1-3)" refers to a straight-chain, branched-chain or cyclic saturated aliphatic hydrocarbon containing the specified number of carbon atoms where one or more hydrogen atoms have been replaced by a of fluoride.
[0024] The term "halogen" refers to fluorine, chlorine, bromine or iodine, preferably to fluorine and chlorine.
[0025] The term "aniline" refers to a compound of the formula C6H5NR13- consisting of a phenyl group attached to an amino group; with "(hetero)-aniline" it is meant that 1-3 nitrogen atoms are present in the aromatic ring, preferably 1 nitrogen atom.
[0026] The term "benzylamine" refers to a compound of the formula C6H5CH2NR13- consisting of a benzyl group, C6H5CH2, attached to an amine functional group; with "(hetero)-benzylamine" is meant that 1-3 nitrogen atoms are present in the aromatic ring, preferably 1 nitrogen atom.
[0027] As used herein, any chemical formula with bonds shown only as solid lines and not as solid minted bonds or perforated minted bonds, or otherwise indicated as having a particular configuration (e.g., R, S) around a or more atoms, contemplates each possible stereoisomer, or mixture of two or more stereoisomers.
[0028] The terms "stereoisomers", "stereoisomeric forms" or "stereochemically isomeric forms" are previously or hereinafter used interchangeably.
[0029] The invention includes all stereoisomers of the compounds of the invention either as a pure stereoisomer or as a mixture of two or more stereoisomers.
[0030] Enantiomers are stereoisomers that are non-superimposable mirror images of each other. A 1:1 mixture of a pair of enantiomers is a racemate or racemic mixture.
[0031] Diastereomers (or diastereoisomers) are stereoisomers that are not enantiomers, i.e., they are not related as mirror images. If a compound contains a double bond, the substituents can be in the E or Z configuration. If a compound contains an at least disubstituted non-aromatic cyclic group, the substituents can be in the cis or trans configuration.
[0032] Therefore, the invention includes enantiomers, diastereomers, racemates, E isomers, Z isomers, cis isomers, trans isomers and mixtures thereof, whenever chemically possible.
[0033] The meaning of all these terms, i.e., enantiomers, diastereomers, racemates, E isomers, Z isomers, cis isomers, trans isomers and mixtures thereof is known to the skilled person.
[0034] Absolute setting is specified according to the Cahn-Ingold-Prelog system. The configuration on an asymmetric atom is specified by R or S. Resolved stereoisomers whose absolute configuration is not known may be designated by (+) or (-) depending on the direction in which they rotate plane polarized light. For example, resolved enantiomers whose absolute configuration is not known may be designated by (+) or (-) depending on the direction in which they rotate plane polarized light.
[0035] When a specific stereoisomer is identified, this means that said stereoisomer is substantially free, ie, associated with less than 50%, preferably less than 20%, more preferably less than 10%, even more preferably less than 5%, in particular less than 2% and most preferably less than 1%, of the other stereoisomers. Thus, when a compound of Formula (I) is for example specified as (R), this means that the compound is substantially free of the (S)-isomer; when a compound of Formula (I) is for example specified as E, this means that the compound is substantially free of the Z-isomer; when a compound of Formula (I) is for example specified as cis, this means that the compound is substantially free of the trans isomer.
[0036] Pharmaceutically acceptable salts of the compounds of formula (I) include acid and base addition salts thereof. Suitable acid addition salts are formed from acids which form non-toxic salts. Suitable base salts are formed from bases which form non-toxic salts.
[0037] The compounds of the invention may also exist in solvated and unsolvated forms. The term "solvate" is used herein to describe a molecular complex comprising the compound of the invention and one or more pharmaceutically acceptable solvent molecules, for example ethanol.
[0038] The term "polymorph" refers to the ability of the compound of the invention to exist in more than one form or crystal structure.
[0039] The compounds of the present invention can be administered as crystalline or amorphous products. They can be obtained for example as solid buffers, powders, or films, by methods such as precipitation, crystallization, lyophilization, spray drying, or evaporative drying. They may be administered alone or in combination with one or more other compounds of the invention or in combination with one or more other drugs. They will generally be administered as a formulation in association with one or more pharmaceutically acceptable excipients. The term "excipient" is used herein to describe any ingredient other than the compound(s) of the invention. The choice of excipient largely depends on factors such as the particular mode of administration, the effect of the excipient on solubility and stability, and the nature of the dosage form.
[0040] The compounds of the present invention or any subgroup thereof may be formulated into various pharmaceutical forms for purposes of administration. As appropriate compositions there may be cited all compositions usually employed for systemic drug administration. To prepare the pharmaceutical compositions of this invention, an effective amount of the particular compound, optionally in addition salt form, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which carrier can take a wide variety of forms depending on the form. of preparation desired for administration. These pharmaceutical compositions are desirably in unitary dosage form suitable, for example, for oral, rectal, or percutaneous administration. For example, in preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs. , emulsions and solutions; or solid carriers such as starches, sugars, kaolin, diluents, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. Also included are solid form preparations which can be converted, immediately before use, to liquid forms. In compositions suitable for percutaneous administration, the carrier optionally comprises a penetration enhancing agent and/or a suitable wetting agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not introduce a significant deleterious effect on the skin. Said additives may facilitate administration to the skin and/or may be useful for preparing the desired compositions. These compositions can be administered in a variety of ways, e.g., as a transdermal patch, as a patch, as an ointment. The compounds of the present invention may also be administered via inhalation or insufflation by means of methods and formulations employed in the art for administration via this route. Thus, in general the compounds of the present invention can be administered to the lungs in the form of a solution, a suspension or a dry powder.
[0041] It is especially advantageous to formulate the aforementioned pharmaceutical compositions in unit dosage form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. Examples of such unit dosage forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, suppositories, injectable solutions or suspensions and the like, and segregated multiples thereof.
[0042] Those of skill in the treatment of infectious diseases will be able to determine the effective amount from the test results presented hereinafter. In general it is contemplated that an effective daily amount would be from 0.01 mg/kg to 50 mg/kg of body weight, more preferably from 0.1 mg/kg to 10 mg/kg of body weight. It may be appropriate to administer the required dose as two, three, four or more sub-doses at appropriate intervals throughout the day. Said sub-doses may be formulated as unit dosage forms, for example, containing 1 to 1000 mg, and in particular 5 to 200 mg of active ingredient per unit dosage form.
[0043] The exact dosage and frequency of administration depend upon the particular compound of formula (I) used, the particular condition being treated, the severity of the condition being treated, the age, weight and general physical condition of the particular patient as well as other medication that the individual may be taking it, as is well known to those skilled in the art. Furthermore, it is evident that the effective amount may be decreased or increased depending on the response of the subject treated and/or depending on the judgment of the physician prescribing the compounds of the present invention. The ranges of effective amounts mentioned above are therefore guidelines only and are not intended to limit the scope or use of the invention to any extent. Preparation of compounds of formula (I)
[0044] Compounds of formula (I) are prepared according to scheme 1. Esters or substituted anthranilic acids (II) were heated under acidic conditions in the presence of excess cyanamide, using an alcoholic solvent (e.g. ethanol) or diglyme according to the method described in the literature (O'Hara et al. JOC (1991) 56, p776). Subsequent amine substitution of 2-amino-4-hydroxyquinazolines (III) can proceed via a coupling agent such as BOP or PyBOP in the presence of DBU and the amine in polar aprotic solvent (eg, DMF). 1:
Experimental Section. General procedure for manufacturing a substituted 2-amino-4-hydroxyquinazoline

[0045] In a 500 mL pressure vessel equipped with a magnetic stir bar were placed 2-amino-5-methoxybenzoic acid (25 g, 149.6 mmol, ethanol (200 mL), cyanamide (9.43 g, 224 mmol), and concentrated HCl (6 mL). The mixture was allowed to stir at 100 °C for 16 h. The reaction mixture was allowed to cool to room temperature and the solids were isolated by filtration and washed with ethanol and DIPE The crude product was dried under vacuum at 50°C to obtain an off-white solid.
[0046] LC-MS m/z = 192(M+H)
[0047] 1H NMR (400MHz, DMSO-d6) δ ppm 3.88 (s, 3H), 6.96 (dd,J=8.2, 3.1Hz, 2H), 7.69 (t, J=8.3 Hz, 1H), 8.28 (l.s., 2H), 12.67 (l.s., 1H) Table I: Compounds of formula (III). The following intermediates were prepared according to the method for preparing III-1.

General manufacturing procedure for compound IV
[0048] Compound III (1.5 mmol) and DBU (3.75 mmol) were dissolved in 5 mL of DMF in a 30 mL glass vial. After 5 minutes BOP (1.5 mmol) was added. The reaction mixture was stirred for 5 minutes and then the amine (2.25 mmol) was added. The reaction mixture was stirred overnight. The crude reaction mixture was purified by prep HPLC. in (RP Vydac Denali C18 - 10 µm, 250 g, 5 cm). Mobile phase (0.25% solution of NH4HCO3 in water, MeOH), the desired fractions were collected, evaporated, dissolved in MeOH and evaporated again to obtain the product as a solid. General procedure for manufacturing compounds 22, 23, 24, 26, 27 and 28
[0049] Compound 8 of formula (I) (see table II) (2.1 g, 6.5 mmol) was dispensed into THF (50 mL), LiOH (409 mg, 9.74 mmol) was added followed by MeOH (5 mL). The reaction mixture was stirred overnight at room temperature. The solvents were evaporated until only water remained. 10 mL of 1M HCl was added and the compound was extracted with 2-methyltetrahydrofuran (2 X 25 mL). The combined organic layers were dried over MgSO4 and the solvents removed under reduced pressure to obtain 2-amino-4-[1-(2-pyridyl)ethylamino]quinazoline-7-carboxylic acid as a white solid.
[0050] 2-Amino-4-[1-(2-pyridyl)ethylamino]quinazoline-7-carboxylic acid (200mg, 0.65mmol) and PyBOP (421mg, 0.81mmol) were dissolved in DMF (5 mL) in a 30 mL glass bottle. After 5 minutes Hunig's base (0.557 mL, 3.23 mmol) was added. The reaction mixture was stirred for 5 minutes and then the amine was added. The reaction mixture was stirred overnight. The crude reaction mixture was purified by prep HPLC. in (RP Vydac Denali C18 - 10 µm, 250 g, 5 cm). Mobile phase (0.25% solution of NH4HCO3 in water, MeOH), the desired fractions were collected, evaporated, dissolved in MeOH and evaporated again to obtain the product as a solid.Procedure for making compound 29
[0051] Compound 12 of formula (I) (see table II) (1500mg, 4.78mmol) and pyridine hydrochloride (3.32g, 28.7mmol) were dissolved in pyridine (20ml) and heated to 120°C for 16 h. Pyridine was removed under reduced pressure. The residual fraction was quenched with a solution (sat., aq.) of NaHCO3. The precipitate was filtered, washed with water and dried under vacuum at 50 °C to give a brown solid which was purified by preparative HPLC (Stationary phase: RP Vydac Denali C18 - 10 μm, 200 g, 5 cm), Mobile phase: solution to 0.25% NH4HCO3 in water, CH3CN, the desired fractions were collected, evaporated, dissolved in MeOH and evaporated again to obtain 2-amino-4-[(5-methylisoxazol-3-yl)methylamino]quinazolin-5 -ol (100 mg) as a solid.
[0052] 2-Amino-4-[(5-methylisoxazol-3-yl)methylamino]quinazolin-5-ol (40mg, 0.15mmol) and Cs2CO3 (144mg, 0.44mmol) were dissolved in DMF (7.5 mL) and stirred at room temperature for 30 minutes. 2-Bromoethyl methyl ether (0.018 mL, 0.18 mmol) was added and the entire mixture was stirred for 16 hours at room temperature. The solvent was removed under reduced pressure and the crude residue was neutralized with 1M HCl and purified by preparative HPLC on (RP Vydac Denali C18 - 10 µm, 250 g, 5 cm). Mobile phase (0.25% solution of NH4HCO3 in water, MeOH), the desired fractions were collected, evaporated, dissolved in MeOH and evaporated again to obtain compound 29 as a solid.Procedure for making compound 30
[0053] A 75 mL stainless steel autoclave was charged under N 2 atmosphere with 2-amino-5-bromo-quinazolin-4-ol (3 g, 12.5 mmol), Pd(OAc) 2 (56 mg, 0 .25 mmol), 1,3-bis(diphenylphosphino)propane (206 mg, 0.5 mmol), potassium acetate (2.45 g, 25 mmol), methanol (25 mL) and THF (30 mL). The autoclave was closed and pressurized to CO gas at 50 bar and the reaction was carried out for 16 hours at 100°C. The formed precipitate was filtered off yielding methyl 2-amino-4-hydroxy-quinazoline-5-carboxylate (2.35 g).
[0054] Methyl 2-amino-4-hydroxy-quinazoline-5-carboxylate (2.35 g) in THF (10 mL) was cooled to 0 °C. Then LiAlH4 was added. The mixture was allowed to reach room temperature and stirred for 16 hours. EtOAc (5 mL) was added dropwise at 0°C, then 3 g of Na2SO4.10H2O was added and the whole mixture was stirred for 30 minutes. The precipitate was filtered, and the filtrate was dried over MgSO4 , filtered and evaporated to dryness to obtain 2-amino-5-(hydroxymethyl)quinazolin-4-ol (750 mg) as a yellow solid.
[0055] 2-Amino-5-(hydroxymethyl)quinazolin-4-ol (300mg, 1.57mmol) was suspended in THF (20mL) with DBU (0.586mL, 3.92mmol), after 5 minutes it was BOP (833 mg, 1.88 mmol) is added. After 15 minutes (5-methyl-3-isoxazolyl)methylamine (0.320 mL, 3.14 mmol) was added. The mixture was stirred for 16 hours at room temperature. The solvent was removed under reduced pressure and the crude product was purified by preparative HPLC on (RP Vydac Denali C18 - 10 µm, 250 g, 5 cm). Mobile phase (0.25% solution of NH4HCO3 in water, MeOH), the desired fractions were collected, evaporated, dissolved in MeOH and evaporated again to obtain compound 30 as a solid (119 mg). 31
[0056] A freshly prepared solution of NaOMe (1.25 mL, 6.25mmol) was added under N2 atmosphere to a mixture of 2-amino-5-bromo-8-fluoro-quinazolin-4-ol (500 mg , 1.94 mmol), copper(I) bromide (39 mg, 0.27 mmol), EtOAc (0.076 mL, 0.78 mmol) in MeOH (5 mL). The mixture was heated in a pressure vessel to reflux for 16 hours. The solvent was removed under reduced pressure. The residue was purified by preparative HPLC (Stationary phase: RP Vydac Denali C18 - 10 μm, 200 g, 5 cm), Mobile phase: 0.25% solution of NH4HCO3 in water, MeOH, the desired fractions were collected, evaporated, dissolved in MeOH and evaporated again to give 2-amino-8-fluoro-5-methoxy-quinazolin-4-ol (150 mg) as a solid.
[0057] 2-Amino-8-fluoro-5-methoxy-quinazolin-4-ol (150mg, 0.72mmol) was dispensed into DMF (10mL), DBU (0.536mL, 3.59mmol) was added. and then BOP reagent (396 mg, 0.90 mmol) was added. The reaction mixture was stirred and, when homogeneous, (5-methyl-3-isoxazolyl)methylamine (0.115 mL, 1.08 mmol) was added. The reaction mixture was stirred 16 hours. The reaction was concentrated under reduced pressure and the residue was purified by preparative HPLC (Stationary phase: RP Vydac Denali C18 - 10 μm, 200 g, 5 cm), Mobile phase: 0.25% solution of NH4HCO3 in water, MeOH, the desired fractions were collected, evaporated, dissolved in MeOH and evaporated again to obtain compound 31 as a solid (64 mg).Procedure for making compound 32
[0058] Compound 31 (52.5 mg, 0.173 mmol) and pyridine hydrochloride (0.12 g, 1.039 mmol) in 1 mL of pyridine were heated to 120 °C for 16 hours. Volatiles were removed under reduced pressure. The residue was quenched with a solution (sat., aq.) of NaHCO 3 . The precipitate was filtered, washed with water and dried under vacuum at 50°C to give 2-amino-8-fluoro-4-[(5-methylisoxazol-3-yl)methylamino]quinazolin-5-ol (10mg) as a brown solid.
[0059] 2-Amino-8-fluoro-4-[(5-methylisoxazol-3-yl)methylamino]quinazolin-5-ol (10mg, 0.035mmol) and Cs2CO3 (33.8mg, 0.104mmol) in DMF (5 mL) was stirred at room temperature for 30 minutes. 2-Chloroethyl methyl ether (4.1 mg, 0.043 mmol) was added and the entire mixture was stirred for 16 hours at room temperature. The solvent was removed under reduced pressure. The residue was dissolved in MeOH and the precipitate (salts) was filtered off. The filtrate was concentrated under reduced pressure and the crude residue was purified by preparative HPLC on (Stationary phase: RP SunFire Prep C18 OBD-10 μm, 30 x 150 mm), Mobile phase: 0.25% solution of NH4HCO3 in water , CH3CN, the desired fractions were collected, evaporated, dissolved in MeOH and evaporated again to obtain compound 32 as a solid (2mg).Table II: Compounds of formula (I). The following compounds were synthesized according to one of the methods described above.

SFC purification methods. General procedure
[0060] Supercritical Fluid Chromatography (SFC) separation was performed with supercritical CO2 and a modifier as specified in the table using a column as specified in the table. Table III: Compounds of formula (I). The following compounds were isolated by SFC separation.

[0061] For all compounds, the first compound to elute was designated as *R.
[0062] *R means a pure enantiomeric configuration of which the absolute stereochemistry is unknown. Analytical Methods general procedure
[0063] Measurement by High Performance Liquid Chromatography (HPLC) was performed using an LC pump, a diode array (DAD) or a UV detector and a column as specified in the respective methods. If necessary, additional detectors were included (see table of methods below).
[0064] The column flow was conducted to the Mass Spectrometer (MS) which was configured with an ion source at atmospheric pressure. It is within the skill of the skilled person to adjust the tuning parameters (eg scan range, residence time...) in order to obtain ions allowing identification of the nominal monoisotropic molecular weight (MW) of the compound. Data acquisition was performed with appropriate software.
[0065] Compounds are described by their experimental retention times (Rt) and ions. If not specified differently in the data table, the reported molecular ion corresponds to [M+H]+ (protonated molecule) and/or [M-H]- (deprotonated molecule). In case the compound is not directly ionizable, the type of adduct is specified (i.e., [M+NH4]+, [M+HCOO]-, etc...). For molecules with multiple isotopic patterns (Br, Cl..), the reported value is that obtained for the lowest isotope mass. All results were obtained with experimental uncertainties that are commonly associated with the method used.
[0066] Hereinafter, "SQD" means Single Quadropole Detector,"MSD" Selective Mass Detector, "TA" room temperature, "BEH" ethylsiloxane/silica bridged hybrid, "DAD" Diode Array Detector, "HSS "High Strength silica. Table IV: LCMS Method Codes (Flow expressed in mL/min; column temperature (T) in °C; Time of
Table V: Compounds of formula (I). The following compounds were characterized according to one of the methods described above.

Biological Activity of compounds of formula (I) Description of Biological Assays Assessment of TLR7 and TLR8 activity
[0067] The ability of compounds to activate human TLR7 and/or TLR8 was evaluated in a cellular reporter assay using HEK293 cells transiently transfected with a TLR7 or TLR8 expression vector and NFKB-IUC reporter construct.
[0068] Briefly, HEK293 cells were grown in culture medium (DMEM supplemented with 10% FCS and 2mM Glutamine). For transfection of cells in 15 cm dishes, cells were detached with Trypsin-EDTA, transfected with a mixture of plasmid CMV-TLR7 or TLR8 (1700 ng), plasmid NFKB-IUC (850 ng) and a transfection reagent and incubated. for 48 h at 37 °C in a humidified 5 % CO2 atmosphere. The transfected cells were then washed in PBS, detached with Trypsin-EDTA and resuspended in medium to a density of 1.25 x 10 5 cells/ml. Forty microliters of cells were then dispensed into each well in 384-well plates, where 200 nL of compound in 100% DMSO was already present. After 6 hours incubation at 37 °C, 5% CO2, luciferase activity was determined by adding 15 μL of Steady Lite Plus substrate (Perkin Elmer) to each well and reading performed on a ViewLux ultraHTS microplate imager ( Perkin Elmer). Dose response curves were generated from measurements performed in quadruplicate. Minimum effective concentration (LEC) values, defined as the concentration that induces an effect that is at least twice the standard deviation of the assay, were determined for each compound.
[0069] Compound toxicity was determined in parallel using a similar dilution series of compound at 40 µL per well of cells transfected with the CMV-TLR7 construct alone (1.25 x 10 5 cells/mL), in 384-well plates. . Cell viability was measured after 6 hours incubation at 37°C, 5% CO2, by adding 15 μL ATP lite (Perkin Elmer) per well and reading on a ViewLux ultraHTS microplate imager (Perkin Elmer). Data were reported as CC50.
[0070] In parallel, a similar dilution series of compound was used (200 nL of compound in 100% DMSO) with 40 µL per well of cells transfected with the NFKB-IUC reporter construct (1.25 x 10 5 cells/mL) . Six hours after incubation at 37 °C, 5% CO2, luciferase activity was determined by adding 15 μL of Steady Lite Plus substrate (Perkin Elmer) to each well and reading performed on a ViewLux ultraHTS microplate imager (Perkin Elmer). Counter tracking data is reported as LEC. Activation of ISRE promoter elements
[0071] The potential of compounds to induce IFN-I was also evaluated by measuring the activation of interferon-stimulated responsive elements (ISRE) by PBMC conditioned media. The ISRE element of the GAAACTGAAACT sequence is highly responsive to the transcription factor STAT1-STAT2-IRF9, activated upon binding of IFN-I to its IFNAR receptor (Clontech, PT3372-5W). The pISRE-Luc plasmid from Clontech (ref. 631913) contains 5 copies of this ISRE element, followed by the firefly luciferase ORF. A HEK293 cell line stably transfected with pISRE-Luc (HEK-ISREluc) was established to characterize the conditioned PBMC cell culture medium.
[0072] Briefly, PBMCs were prepared from buffy coats of at least two donors using a standard Ficoll centrifugation protocol. Isolated PBMCs were resuspended in RPMI medium supplemented with 10% human AB serum and 2 x 10 5 cells/well were dispensed into 384-well plates containing compounds (total volume 70 µL). After overnight incubation, 10 µL of supernatant was transferred to 384-well plates containing 5 x 10 3 HEK-ISREluc cells/well in 30 µL (plated the day before). After 24 hours of incubation, activation of ISRE elements was measured by assessing luciferase activity using 40 μL/well of Steady Lite Plus substrate (Perkin Elmer) and measured with a ViewLux ultraHTS microplate imager (Perkin Elmer). The stimulatory activity of each compound on HEK-ISREluc cells was reported as the LEC value, defined as the concentration of compound applied to the PBMCs resulting in a luciferase activity at least twice the standard deviation of the assay. The LEC in turn indicates the degree of ISRE activation after transfer of a defined amount of PBMC culture medium. Recombinant interferon α-2a (Roferon-A) was used as a standard control compound.TABLE VI: BIOLOGICAL ACTIVITY.

NA = not available. All compounds showed no toxicity up to the highest tested concentrate. All compounds showed no activity (LEC >25 μM) in the HEK 293 NF-kB counterscreen assay described above.

权利要求:
Claims (5)
[0001]
1. Compound, characterized by the fact that it has the formula (I)
[0002]
2. Pharmaceutical composition, characterized in that it comprises a compound of formula (I) or a pharmaceutically acceptable salt or tautomer(s) thereof as defined in claim i, together with one or more pharmaceutically acceptable excipients, diluents or carriers.
[0003]
3. A compound of formula (I) or a pharmaceutically acceptable salt or tautomer(s) thereof according to claim i, characterized in that it is for use as a medicament.
[0004]
4. Pharmaceutical composition according to claim 2, characterized in that it is for use as a medicine.
[0005]
5. A compound of formula (I) according to claim i, characterized in that it is selected from the group consisting of:

类似技术:

公开号 | 公开日 | 专利标题

BR112015011036B1|2022-02-01|Heterocyclic Substituted 2-Amino-quinazoline Derivatives, Pharmaceutical Composition

JP6401788B2|2018-10-10|Thieno [3,2-d] pyrimidine derivatives for viral infection treatment

US9284304B2|2016-03-15|Substituted pyrimidines as toll-like receptor modulators

CN104837840B|2017-08-08|Pyrrolo- [3,2 d] pyrimidine derivatives for treating virus infection and other diseases

ES2716811T3|2019-06-17|Piperidinopyrimidine derivatives for the treatment of viral infections

JP2019524662A|2019-09-05|Dihydropyranopyrimidines for the treatment of viral infections

IL237871A|2017-04-30|1,2,4-triazine derivatives for the treatment of viral infections

JP6377139B2|2018-08-22|Pyridone derivatives for the treatment of viral infections and further diseases

BR112014019699B1|2021-12-07|PIPERIDINO-PYRIMIDINE DERIVATIVES, THEIR USE IN THE TREATMENT OF VIRAL INFECTIONS AND THE PHARMACEUTICAL COMPOSITION THAT COMPRISES THEM

BR112015002524B1|2021-11-03|ALKYLPYRIMIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITION INCLUDING THEM AND THE USE OF THE SAME

NZ709769B2|2021-02-02|2-aminopyrimidine derivatives for the treatment of viral infections

同族专利:

公开号 | 公开日

EP2925729B1|2017-10-18|

US20150284339A1|2015-10-08|

US10723707B2|2020-07-28|

US10253003B2|2019-04-09|

JP2015537020A|2015-12-24|

CN105051018B|2019-09-20|

UA118341C2|2019-01-10|

DK2925729T3|2018-01-22|

CL2015001265A1|2015-08-28|

MX361585B|2018-12-11|

EA035431B1|2020-06-15|

EA201590931A1|2016-01-29|

WO2014076221A1|2014-05-22|

MY171115A|2019-09-26|

KR102253773B1|2021-05-20|

NZ748345A|2020-04-24|

US20190330160A1|2019-10-31|

PH12015500983A1|2015-08-03|

CN105051018A|2015-11-11|

CA2886635C|2021-01-05|

AU2013346793B2|2018-03-08|

PL2925729T3|2018-04-30|

IL237864A|2017-08-31|

CA2886635A1|2014-05-22|

PH12015500983B1|2015-08-03|

JP6297055B2|2018-03-20|

BR112015011036A2|2017-07-11|

US20170349557A1|2017-12-07|

US9663474B2|2017-05-30|

SG11201503042QA|2015-06-29|

AU2013346793A1|2015-04-09|

EP2925729A1|2015-10-07|

NZ706226A|2019-09-27|

KR20150083842A|2015-07-20|

ES2655843T3|2018-02-21|

MX2015006197A|2015-08-10|

引用文献:

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

JP2610889B2|1987-09-03|1997-05-14|日本臓器製薬株式会社|New crosslinked adenine derivatives|

WO1995034311A1|1994-06-13|1995-12-21|Merck & Co., Inc.|Piperazine compounds promote release of growth hormone|

JP4667543B2|1996-07-03|2011-04-13|大日本住友製薬株式会社|New purine derivatives|

EA002769B1|1996-08-28|2002-08-29|Пфайзер Инк.|Substituted 6,5-hetero-bicyclic derivatives|

DE69717867T2|1996-10-04|2003-10-02|Kyorin Seiyaku Kk|PYRAZOLOPYRIDYLPYRAZINONE DERIVATIVES AND A METHOD FOR THE PRODUCTION THEREOF|

AR012634A1|1997-05-02|2000-11-08|Sugen Inc|QUINAZOLINE BASED COMPOUND, FAMACEUTICAL COMPOSITION THAT UNDERSTANDS IT, METHOD TO SYNTHESIZE IT, ITS USE, METHODS OF MODULATION OF THE DESERINE / TREONIN PROTEIN-KINASE FUNCTION AND IN VITRO METHOD TO IDENTIFY COMPOUNDS THAT MODULATE|

US6339089B2|1997-08-13|2002-01-15|Fujirebio Inc.|Pyrimidine nucleus-containing compound and a medicament containing the same for a blood oxygen partial pressure amelioration, and a method for preparing the same|

ES2205573T3|1997-11-28|2004-05-01|Sumitomo Pharmaceuticals Company, Limited|NEW HETEROCICLIC COMPOUNDS.|

TW572758B|1997-12-22|2004-01-21|Sumitomo Pharma|Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives|

US6187777B1|1998-02-06|2001-02-13|Amgen Inc.|Compounds and methods which modulate feeding behavior and related diseases|

EP1056742B1|1998-02-17|2003-07-23|Tularik, Inc.|Anti-viral pyrimidine derivatives|

US6110929A|1998-07-28|2000-08-29|3M Innovative Properties Company|Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof|

JP4315300B2|1998-08-10|2009-08-19|大日本住友製薬株式会社|Novel quinazoline derivatives|

JP4342007B2|1998-08-10|2009-10-14|大日本住友製薬株式会社|Quinazoline derivatives|

WO2000012487A1|1998-08-27|2000-03-09|Sumitomo Pharmaceuticals Co., Ltd.|Pyrimidine derivatives|

US6583148B1|1999-04-08|2003-06-24|Krenitsky Pharmaceuticals, Inc.|Neurotrophic substituted pyrimidines|

US6503908B1|1999-10-11|2003-01-07|Pfizer Inc|Pharmaceutically active compounds|

EP1382603B1|2001-04-26|2008-07-23|Eisai R&D Management Co., Ltd.|Nitrogenous fused-ring compound having pyrazolyl group as substituent and medicinal composition thereof|

WO2002088079A2|2001-05-01|2002-11-07|Bristol-Myers Squibb Company|Dual inhibitors of pde 7 and pde 4|

WO2003055890A1|2001-12-21|2003-07-10|Bayer Pharmaceuticals Corporation|Thienopyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents|

TW200407143A|2002-05-21|2004-05-16|Squibb Bristol Myers Co|Pyrrolotriazinone compounds and their use to treat diseases|

US7091232B2|2002-05-21|2006-08-15|Allergan, Inc.|4- imidazole-2-thiones, 4- imidazole-2-thiones, 4- imidazol-2-ones and 4- imidazol-2-ones and related compounds|

WO2003104230A1|2002-06-07|2003-12-18|協和醱酵工業株式会社|Bicyclic pyrimidine derivatives|

KR101111085B1|2002-09-27|2012-04-12|다이닛본 스미토모 세이야꾸 가부시끼가이샤|Novel adenine compound and use thereof|

US8455458B2|2002-10-16|2013-06-04|Arthrodynamic Technologies, Animal Health Division, Inc.|Composition and method for treating connective tissue damage|

WO2005025583A2|2003-09-05|2005-03-24|Anadys Pharmaceuticals, Inc.|Tlr7 ligands for the treatment of hepatitis c|

EP1728792A4|2004-03-26|2010-12-15|Dainippon Sumitomo Pharma Co|8-oxoadenine compound|

UA86798C2|2004-03-26|2009-05-25|ДАЙНИППОН СУМИТОМО ФАРМА Ко., ЛТД.|9-substituted 8-oxoadenine compound|

WO2007084413A2|2004-07-14|2007-07-26|Ptc Therapeutics, Inc.|Methods for treating hepatitis c|

CA2575002C|2004-08-10|2015-01-20|Janssen Pharmaceutica N.V.|Hiv inhibiting 1,2,4-triazin-6-one derivatives|

AU2005304040B2|2004-11-09|2009-04-23|F. Hoffmann-La Roche Ag|Aminoquinazolines compounds|

US7498409B2|2005-03-24|2009-03-03|Schering Corporation|Screening assay for TLR7, TLR8 and TLR9 agonists and antagonists|

AR054122A1|2005-05-12|2007-06-06|Tibotec Pharm Ltd|PIRIDO [2,3-D] USEFUL PYRIMIDES AS HCV INHIBITORS, AND METHODS FOR THE PREPARATION OF THE SAME|

US7994360B2|2005-05-16|2011-08-09|Xtl Biopharmaceuticals Ltd.|Benzofuran compounds|

EP1924564B1|2005-09-01|2016-11-09|F.Hoffmann-La Roche Ag|Diaminopyrimidines as p2x3 and p2x2/3 modulators|

US20090192153A1|2005-09-22|2009-07-30|Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan|Novel adenine compound|

WO2007056208A2|2005-11-02|2007-05-18|Cytovia, Inc.|N-arylalkyl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof|

WO2007063934A1|2005-12-02|2007-06-07|Mitsubishi Tanabe Pharma Corporation|Alicyclic heterocyclic compound|

KR20080085232A|2006-02-17|2008-09-23|화이자 리미티드|3-deazapurine derivatives as tlr7 modulators|

WO2008009078A2|2006-07-20|2008-01-24|Gilead Sciences, Inc.|4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections|

WO2008009077A2|2006-07-20|2008-01-24|Gilead Sciences, Inc.|4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections|

ZA200904531B|2006-12-07|2010-09-29|Hoffmann La Roche|Phosphoinositide 3-kinase inhibitor compounds and methods of use|

CA2672250C|2006-12-20|2013-04-30|Ian Stansfield|Antiviral indoles|

JP2008222557A|2007-03-08|2008-09-25|Kotobuki Seiyaku Kk|PYRROLO[3,2-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AS EFFECTIVE COMPONENT|

PT2132209E|2007-03-19|2014-04-15|Astrazeneca Ab|9-substituted-8-oxo-adenine compounds as toll-like receptor modulators|

AR065784A1|2007-03-20|2009-07-01|Dainippon Sumitomo Pharma Co|DERIVATIVES OF 8-OXO ADENINE, DRUGS THAT CONTAIN THEM AND USES AS THERAPEUTIC AGENTS FOR ALLERGIC, ANTIVIRAL OR ANTIBACTERIAL DISEASES.|

EP2138497A4|2007-03-20|2012-01-04|Dainippon Sumitomo Pharma Co|Novel adenine compound|

WO2008147697A1|2007-05-22|2008-12-04|Boehringer Ingelheim International Gmbh|Benzimidazolone chymase inhibitors|

EA024359B1|2007-06-29|2016-09-30|Джилид Сайэнс, Инк.|Purine derivatives and their use as modulators of toll-like receptor 7|

AU2008287421A1|2007-08-10|2009-02-19|Glaxosmithkline Llc|Nitrogen containing bicyclic chemical entities for treating viral infections|

JP2010538004A|2007-08-28|2010-12-09|アイアールエム・リミテッド・ライアビリティ・カンパニー|2-Biphenylamino-4-aminopyrimidine derivatives as kinase inhibitors|

WO2009030998A1|2007-09-05|2009-03-12|Coley Pharmaceutical Group, Inc.|Pyrimidine compounds as toll-like receptor agonists|

PE20091236A1|2007-11-22|2009-09-16|Astrazeneca Ab|PYRIMIDINE DERIVATIVES AS IMMUNOMODULATORS OF TLR7|

DK2238142T3|2007-12-24|2012-10-08|Janssen R & D Ireland|Macrocyclic indoles such as hepatitis C virus inhibitors|

WO2009099650A2|2008-02-07|2009-08-13|Carson Dennis A|Treatment of bladder diseases with a tlr7 activator|

US8461107B2|2008-04-28|2013-06-11|Merck Sharp & Dohme Corp.|HCV NS3 protease inhibitors|

US8946239B2|2008-07-10|2015-02-03|Duquesne University Of The Holy Spirit|Substituted pyrrolo, -furano, and cyclopentylpyrimidines having antimitotic and/or antitumor activity and methods of use thereof|

UY31982A|2008-07-16|2010-02-26|Boehringer Ingelheim Int|DERIVATIVES OF 1,2-DIHYDROPIRIDIN-3-CARBOXAMIDS N-SUBSTITUTED|

EA201101650A1|2009-05-21|2012-07-30|Астразенека Аб|NEW PYRIMIDINE DERIVATIVES AND THEIR APPLICATION IN THE TREATMENT OF MALIGNANT NONFORMS AND THE FOLLOWING DISEASES|

US8637525B2|2009-07-31|2014-01-28|Bristol-Myers Squibb Company|Compounds for the reduction of beta-amyloid production|

EP2491033A4|2009-10-20|2013-03-13|Eiger Biopharmaceuticals Inc|Azaindazoles to treat flaviviridae virus infection|

KR101094446B1|2009-11-19|2011-12-15|한국과학기술연구원|2,4,7-Substituted thieno[3,2-d]pyrimidine compounds as protein kinase inhibitors|

JP2013032290A|2009-11-20|2013-02-14|Dainippon Sumitomo Pharma Co Ltd|Novel fused pyrimidine derivative|

DE102010040233A1|2010-09-03|2012-03-08|Bayer Schering Pharma Aktiengesellschaft|Bicyclic aza heterocycles and their use|

WO2012066335A1|2010-11-19|2012-05-24|Astrazeneca Ab|Phenol compounds als toll -like receptor 7 agonists|

WO2012067269A1|2010-11-19|2012-05-24|Dainippon Sumitomo Pharma Co., Ltd.|Aminoalkoxyphenyl compounds and their use in the treatment of disease|

WO2012079079A1|2010-12-10|2012-06-14|President And Fellows Of Harvard College|Production of induced pluripotent stem cells|

CA2835229C|2011-05-18|2020-05-05|Janssen R&D Ireland|Quinazoline derivatives for the treatment of viral infections and further diseases|

DK2776439T3|2011-11-09|2018-10-22|Janssen Sciences Ireland Uc|PURINE DERIVATIVES FOR TREATING VIRUS INFECTIONS|

IN2014MN01736A|2012-02-08|2015-07-10|Janssen R & D Ireland|

RS61664B1|2012-04-24|2021-04-29|Vertex Pharma|Dna-pk inhibitors|

SI2872515T1|2012-07-13|2016-10-28|Janssen Sciences Ireland Uc|Macrocyclic purines for the treatment of viral infections|

EP2712866A1|2012-10-01|2014-04-02|Centre National de la Recherche Scientifique |1,2,4-triazine derivatives for the treatment of viral infections|

EA034650B1|2012-10-05|2020-03-03|Янссен Сайенсиз Айрлэнд Юси|Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases|

LT2906563T|2012-10-10|2018-06-11|Janssen Sciences Ireland Uc|Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases|

US9663474B2|2012-11-16|2017-05-30|Janssen Sciences Ireland Uc|Heterocyclic substituted 2-amino quinazoline derivatives for the treatment of viral infections|

CN105189468B|2013-02-21|2018-10-30|爱尔兰詹森科学公司|2- aminopyridine derivatives for treating viral infection|

AU2014242954B2|2013-03-29|2018-03-15|Janssen Sciences Ireland Uc|Macrocyclic deaza-purinones for the treatment of viral infections|

NZ714519A|2013-07-30|2021-07-30|Janssen Sciences Ireland Uc|Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections|

WO2016007966A2|2014-07-11|2016-01-14|Northwestern University|2-imidazolyl-pyrimidine scaffolds as potent and selective inhibitors of neuronal nitric oxide synthase|HUE055286T2|2011-04-08|2021-11-29|Janssen Sciences Ireland Unlimited Co|Pyrimidine derivatives for the treatment of viral infections|

DK2776439T3|2011-11-09|2018-10-22|Janssen Sciences Ireland Uc|PURINE DERIVATIVES FOR TREATING VIRUS INFECTIONS|

SI2872515T1|2012-07-13|2016-10-28|Janssen Sciences Ireland Uc|Macrocyclic purines for the treatment of viral infections|

LT2906563T|2012-10-10|2018-06-11|Janssen Sciences Ireland Uc|Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases|

US9663474B2|2012-11-16|2017-05-30|Janssen Sciences Ireland Uc|Heterocyclic substituted 2-amino quinazoline derivatives for the treatment of viral infections|

CN105189468B|2013-02-21|2018-10-30|爱尔兰詹森科学公司|2- aminopyridine derivatives for treating viral infection|

AU2014242954B2|2013-03-29|2018-03-15|Janssen Sciences Ireland Uc|Macrocyclic deaza-purinones for the treatment of viral infections|

UA117590C2|2013-06-27|2018-08-27|ЯНССЕН САЙЄНСЕЗ АЙРЛЕНД ЮСі|Solar protection glazing|

NZ714519A|2013-07-30|2021-07-30|Janssen Sciences Ireland Uc|Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections|

CA2995004A1|2015-08-26|2017-03-02|Gilead Sciences, Inc.|Deuterated toll-like receptor modulators|

MA42818A|2015-09-15|2018-07-25|Gilead Sciences Inc|TOLL-TYPE RECEPTOR MODULATORS FOR HIV TREATMENT|

KR102165120B1|2015-12-15|2020-10-13|길리애드 사이언시즈, 인코포레이티드|Human immunodeficiency virus neutralizing antibodies|

CN108473493A|2016-01-07|2018-08-31|爱尔兰詹森科学公司|Functionalized valeric acid for influenza infection|

BR102017010009A2|2016-05-27|2017-12-12|Gilead Sciences, Inc.|COMPOUNDS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION|

CA3025633C|2016-05-27|2021-02-23|Gilead Sciences, Inc.|Methods for treating hepatitis b virus infections using ns5a, ns5b or ns3 inhibitors|

JP2019524662A|2016-07-01|2019-09-05|ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー|Dihydropyranopyrimidines for the treatment of viral infections|

UY37374A|2016-08-26|2018-03-23|Gilead Sciences Inc|SUBSTITUTED PIRROLIZINE COMPOUNDS AND USES OF THE SAME|

US10370342B2|2016-09-02|2019-08-06|Gilead Sciences, Inc.|Toll like receptor modulator compounds|

EP3507288B1|2016-09-02|2020-08-26|Gilead Sciences, Inc.|4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators|

CN109790154A|2016-09-29|2019-05-21|爱尔兰詹森科学公司|For treating the pyrimidine prodrug of virus infection and other disease|

AR110768A1|2017-01-31|2019-05-02|Gilead Sciences Inc|CRYSTAL FORMS OF TENOFOVIR ALAFENAMIDA|

AR112412A1|2017-08-17|2019-10-23|Gilead Sciences Inc|CHOLINE SALT FORMS OF AN HIV CAPSID INHIBITOR|

AR112413A1|2017-08-17|2019-10-23|Gilead Sciences Inc|SOLID FORMS OF AN HIV CAPSID INHIBITOR|

KR20200043439A|2017-08-22|2020-04-27|길리애드 사이언시즈, 인코포레이티드|Therapeutic heterocyclic compounds|

WO2019084060A1|2017-10-24|2019-05-02|Silverback Therapeutics, Inc.|Conjugates and methods of use thereof for selective delivery of immune-modulatory agents|

CN111601822A|2017-12-15|2020-08-28|希沃尔拜克治疗公司|Antibody construct-drug conjugates for the treatment of hepatitis|

US10966999B2|2017-12-20|2021-04-06|Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I.|3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein|

US11203610B2|2017-12-20|2021-12-21|Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I.|2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein|

CN109867627B|2018-02-07|2021-05-07|南方医科大学|Substituted phenol beta-aminoalcohol derivative and its preparation method and use|

CA3089590A1|2018-02-15|2019-08-22|Gilead Sciences, Inc.|Pyridine derivatives and their use for treating hiv infection|

KR20200124716A|2018-02-26|2020-11-03|길리애드 사이언시즈, 인코포레이티드|Substituted pyrrolysine compounds as inhibitors of HBV replication|

TW201945003A|2018-03-01|2019-12-01|愛爾蘭商健生科學愛爾蘭無限公司|2,4-diaminoquinazoline derivatives and medical uses thereof|

EP3774883A1|2018-04-05|2021-02-17|Gilead Sciences, Inc.|Antibodies and fragments thereof that bind hepatitis b virus protein x|

TW202005654A|2018-04-06|2020-02-01|捷克科學院有機化學與生物化學研究所|2'2'-cyclic dinucleotides|

TW202005655A|2018-04-06|2020-02-01|捷克科學院有機化學與生物化學研究所|2'3'-cyclic dinucleotides|

TW202010503A|2018-04-06|2020-03-16|捷克科學院有機化學與生物化學研究所|3’3’－cyclic dinucleotides|

TW201945388A|2018-04-12|2019-12-01|美商精密生物科學公司|Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis B virus genome|

US10899735B2|2018-04-19|2021-01-26|Gilead Sciences, Inc.|PD-1/PD-L1 inhibitors|

TW202014193A|2018-05-03|2020-04-16|捷克科學院有機化學與生物化學研究所|2’3’-cyclic dinucleotides comprising carbocyclic nucleotide|

CN112368052A|2018-07-03|2021-02-12|吉利德科学公司|Antibodies targeting HIV GP120 and methods of use|

CA3104398A1|2018-07-06|2020-01-09|Gilead Sciences, Inc.|Therapeutic heterocyclic compounds|

JP2021529806A|2018-07-06|2021-11-04|ギリアードサイエンシーズ，インコーポレイテッド|Therapeutic heterocyclic compounds|

CA3103286A1|2018-07-13|2020-01-16|Gilead Sciences, Inc.|Pd-1/pd-l1 inhibitors|

WO2020028097A1|2018-08-01|2020-02-06|Gilead Sciences, Inc.|Solid forms of -11--12--3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid|

JP2022500414A|2018-09-12|2022-01-04|シルバーバックセラピューティックスインコーポレイテッド|Methods and Compositions for Treating Diseases with Immunostimulatory Conjugates|

EP3860717A1|2018-10-03|2021-08-11|Gilead Sciences, Inc.|Imidozopyrimidine derivatives|

WO2020078455A1|2018-10-19|2020-04-23|南京明德新药研发有限公司|Tlr8 agonist|

WO2020086556A1|2018-10-24|2020-04-30|Gilead Sciences, Inc.|Pd-1/pd-l1 inhibitors|

EP3873608A1|2018-10-31|2021-09-08|Gilead Sciences, Inc.|Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity|

CR20210215A|2018-10-31|2021-06-17|Gilead Sciences Inc|Substituted 6-azabenzimidazole compounds as hpk1 inhibitors|

WO2020162705A1|2019-02-08|2020-08-13|성균관대학교산학협력단|Toll-like receptor 7 or 8 agonist-cholesterol complex, and use of same|

WO2020176510A1|2019-02-25|2020-09-03|Gilead Sciences, Inc.|Protein kinase c agonists|

WO2020176505A1|2019-02-25|2020-09-03|Gilead Sciences, Inc.|Protein kinase c agonists|

WO2020178770A1|2019-03-07|2020-09-10|Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I.|3'3'-cyclic dinucleotides and prodrugs thereof|

WO2020178769A1|2019-03-07|2020-09-10|Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I.|2'3'-cyclic dinucleotides and prodrugs thereof|

WO2020178768A1|2019-03-07|2020-09-10|Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I.|3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator|

EP3956329A1|2019-04-17|2022-02-23|Gilead Sciences, Inc.|Solid forms of a toll-like receptor modulator|

WO2020214663A1|2019-04-17|2020-10-22|Gilead Sciences, Inc.|Solid forms of a toll-like receptor modulator|

TW202110481A|2019-05-21|2021-03-16|美商基利科學股份有限公司|Methods of identifying hiv patients sensitive to therapy with gp120 v3 glycan-directed antibodies|

WO2020237025A1|2019-05-23|2020-11-26|Gilead Sciences, Inc.|Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors|

WO2020255038A1|2019-06-18|2020-12-24|Janssen Sciences Ireland Unlimited Company|Combination of hepatitis b virusvaccines and pyridopyrimidine derivatives|

WO2020255039A1|2019-06-18|2020-12-24|Janssen Sciences Ireland Unlimited Company|Combination of hepatitis b virusvaccines and quinazoline derivatives|

AU2020298222A1|2019-06-19|2022-01-20|Silverback Therapeutics, Inc.|Anti-mesothelin antibodies and immunoconjugates thereof|

CA3142513A1|2019-06-25|2020-12-30|Gilead Sciences, Inc.|Flt3l-fc fusion proteins and methods of use|

US20210017255A1|2019-07-16|2021-01-21|Gilead Sciences, Inc.|Hiv vaccines and methods of making and using|

WO2021011891A1|2019-07-18|2021-01-21|Gilead Sciences, Inc.|Long-acting formulations of tenofovir alafenamide|

WO2021034804A1|2019-08-19|2021-02-25|Gilead Sciences, Inc.|Pharmaceutical formulations of tenofovir alafenamide|

WO2021067181A1|2019-09-30|2021-04-08|Gilead Sciences, Inc.|Hbv vaccines and methods treating hbv|

WO2021067644A1|2019-10-01|2021-04-08|Silverback Therapeutics, Inc.|Combination therapy with immune stimulatory conjugates|

WO2021076908A1|2019-10-18|2021-04-22|Forty Seven, Inc.|Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia|

WO2021087064A1|2019-10-31|2021-05-06|Forty Seven, Inc.|Anti-cd47 and anti-cd20 based treatment of blood cancer|

TW202128714A|2019-11-12|2021-08-01|美商基利科學股份有限公司|Mcl1 inhibitors|

WO2021113765A1|2019-12-06|2021-06-10|Precision Biosciences, Inc.|Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome|

WO2021130638A1|2019-12-24|2021-07-01|Carna Biosciences, Inc.|Diacylglycerol kinase modulating compounds|

WO2021163064A2|2020-02-14|2021-08-19|Jounce Therapeutics, Inc.|Antibodies and fusion proteins that bind to ccr8 and uses thereof|

US11179473B2|2020-02-21|2021-11-23|Silverback Therapeutics, Inc.|Nectin-4 antibody conjugates and uses thereof|

WO2021185312A1|2020-03-18|2021-09-23|正大天晴药业集团股份有限公司|Crystalline form of tlr8 agonist|

WO2021188959A1|2020-03-20|2021-09-23|Gilead Sciences, Inc.|Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same|

WO2021222522A1|2020-05-01|2021-11-04|Gilead Sciences, Inc.|Cd73 inhibiting 2,4-dioxopyrimidine compounds|

WO2021236944A1|2020-05-21|2021-11-25|Gilead Sciences, Inc.|Pharmaceutical compositions comprising bictegravir|

WO2021262990A1|2020-06-25|2021-12-30|Gilead Sciences, Inc.|Capsid inhibitors for the treatment of hiv|

WO2022006327A1|2020-07-01|2022-01-06|Silverback Therapeutics, Inc.|Anti-asgr1 antibody conjugates and uses thereof|

WO2022031894A1|2020-08-07|2022-02-10|Gilead Sciences, Inc.|Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use|

法律状态:
2018-01-23| B07D| Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]|

2019-08-13| B07E| Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]|Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |

2019-12-17| B06U| Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]|

2021-09-08| B06A| Patent application procedure suspended [chapter 6.1 patent gazette]|

2021-11-23| B09A| Decision: intention to grant [chapter 9.1 patent gazette]|

2022-02-01| B16A| Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]|Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/11/2013, OBSERVADAS AS CONDICOES LEGAIS. |

优先权:

申请号 | 申请日 | 专利标题

EP12192970.7|2012-11-16|

EP12192970|2012-11-16|

PCT/EP2013/073901|WO2014076221A1|2012-11-16|2013-11-15|Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections|

[返回顶部]